A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; Lacnotuzumab (Primary) ; LAG 525 (Primary) ; Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 10 Apr 2019 Planned End Date changed from 14 Jul 2020 to 9 Oct 2020.
- 10 Apr 2019 Planned primary completion date changed from 14 Jul 2020 to 9 Oct 2020.
- 15 Feb 2019 Planned End Date changed from 3 Aug 2020 to 14 Jul 2020.